BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 169 filers reported holding BRIDGEBIO PHARMA INC in Q4 2020. The put-call ratio across all filers is 0.33 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,635 | +59.0% | 61,976 | +3.7% | 0.00% | – |
| Q2 2023 | $1,028 | +12.2% | 59,756 | +8.3% | 0.00% | – |
| Q1 2023 | $916 | +80.7% | 55,201 | -17.0% | 0.00% | – |
| Q4 2022 | $507 | -99.9% | 66,522 | -20.1% | 0.00% | – |
| Q3 2022 | $828,000 | +1.1% | 83,286 | -7.7% | 0.00% | – |
| Q2 2022 | $819,000 | +21.9% | 90,197 | +36.2% | 0.00% | – |
| Q1 2022 | $672,000 | -4.0% | 66,224 | +57.7% | 0.00% | – |
| Q4 2021 | $700,000 | -66.4% | 41,986 | -5.6% | 0.00% | – |
| Q3 2021 | $2,085,000 | -93.7% | 44,493 | -91.8% | 0.00% | -100.0% |
| Q2 2021 | $33,111,000 | -11.3% | 543,165 | -10.4% | 0.00% | -25.0% |
| Q1 2021 | $37,329,000 | +1637.0% | 605,990 | +1905.7% | 0.00% | – |
| Q4 2020 | $2,149,000 | +111.5% | 30,214 | +11.6% | 0.00% | – |
| Q3 2020 | $1,016,000 | +73.4% | 27,073 | +50.8% | 0.00% | – |
| Q2 2020 | $586,000 | +14.0% | 17,955 | +1.4% | 0.00% | – |
| Q1 2020 | $514,000 | – | 17,711 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
| Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
| Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
| Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
| M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
| BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
| Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
| SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |